AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that one abstract has been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL. The full abstract can now be viewed on the NKF website at http://www.kidney.org/news/meetings/clinical/index.cfm.

“Aspects of IV Ferumoxytol Administration and Acute Adverse Events in CKD Patients”

The following abstract will be presented:

• “Aspects of IV Ferumoxytol Administration and Acute Adverse Events in CKD Patients” (Sharma et al). Poster presentation; 6:00 pm – 7:30 pm, Wednesday, April 14. Using pooled data from 3 pivotal studies in patients with iron deficiency anemia and CKD, both on and not on dialysis, the analyses evaluated the safety of 510 mg ferumoxytol by injection number and interval between injections. The results of the analyses support that the safety profile of ferumoxytol is comparable between first and second administration regardless of the number of days in between the administrations.